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Abstract
Background: In epidemic regions of the world, brucellosis is a reemerging zoonosis with minimal mortality but is
a serious public hygiene problem. Currently, there are various methods for brucellosis diagnosis, however few of
them are available to be used to diagnose, especially for serious cross-reaction with other bacteria.
Method: To overcome this disadvantage, we explored a novel multi-epitope recombinant protein as human brucellosis
diagnostic antigen. We established an indirect enzyme-linked immunosorbent assay (ELISA) based on this recombinant
protein. 248 sera obtained from three different groups including patients with brucellosis (146 samples), non-brucellosis
patients (82 samples), and healthy individuals (20 samples) were tested by indirect ELISA. To evaluate the assay,
a receiver-operating characteristic (ROC) analysis and immunoblotting were carried out using these characterized
serum samples.
Results: For this test, the area under the ROC curve was 0.9409 (95 % confidence interval, 0.9108 to 0.9709), and
a sensitivity of 88.89 % and a specificity of 85.54 % was given with a cutoff value of 0.3865 from this ROC analysis.
The Western blot results indicate that it is feasible to differentiate human brucellosis and non-brucellosis with the
newly established method based on this recombinant protein.
Conclusion: Our results obtained high diagnostic accuracy of the ELISA assay which encourage the use of this
novel recombinant protein as diagnostic antigen to implement serological diagnosis of brucellosis.
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Background
Brucella spp. are Gram-negative, facultative, intracellular
bacterial pathogens that cause brucellosis, an infectious
disease affecting animals and humans [1]. Based on the
difference in pathogenicity and host preference, three
main human brucellosis pathogens, B. melitensis, B. abor-
tus, and B. suis (whose preferred natural host animals are
sheep and goats, cattle, and swine, respectively), can infect
humans, involving any organ or system of the body, and
lead to serious complications with important public health
issues [2]. The infection is primarily transmitted by con-
sumption of unpasteurized dairy products, direct contact
with infected animals, handling of cultures or clinical
specimens. The disease remains endemic in many regions
of the world, including Latin America, the Middle East,
Africa, Asia, and the Mediterranean basin, affecting ap-
proximately 500,000 people annually around the world
[3]. As the largest developing country in the world, the in-
cidence of human brucellosis has rapidly increased in
China since 1995 [4]. According to data from the Chinese
Center for Disease Control and Prevention (CDC), more
than 57,000 human cases were identified in 2014 (http://
www.nhfpc.gov.cn/jkj /s3578/ 201502/847c041a3bac4c3e8
44f17309be0cabd.shtml). According to the previous study,
brucellosis is mainly distributed in some of the northern
provinces of China, accounted for >90 % of the re-
ported cases. Jilin province has the fourth highest inci-
dence, with the annual incidence ranging from 50 to
100 per 1000,000 [5].
Because of a deficiency of clinical pathognomonic symp-
toms, a prompt and accurate diagnosis is important.
Current methods used for identification of brucellosis
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include traditional culture-, immunological-, and molecular-
based methods, which usually follow a bacterial enrich-
ment step. Blood culture, which was considered the golden
standard method, provides the definitive diagnosis of bru-
cellosis but may not provide a positive result for all pa-
tients [6]; it presents several other drawbacks, such as
being time-consuming and dangerous for personnel, and
few laboratories have suitable culture conditions [7]. Al-
though polymerase chain reaction (PCR) and real-time
PCR assays are very promising, infrastructure, equipment,
and expertise are lacking in developing countries [8].There-
fore, serological tests, such as the enzyme-linked immuno-
sorbent assay (ELISA) and standard tube agglutination test
(SAT), have become the most useful tools for diagnosis of
brucellosis. In particular, ELISA can provide higher sensitiv-
ity and specificity compared with SAT [9]. The crucial
part of ELISAs is a sensitive and specific diagnostic anti-
gen. Several immunogenic Brucella spp. surface-exposed
outer membrane proteins (OMPs), such as OMP16 [10],
OMP25 [11], OMP2b [12], and OMP31 [13], and periplas-
mic protein 26 (BP26) [14] have been previously identi-
fied, which indicates these immunoreactive proteins are
potential candidates of diagnostic antigens for ELISAs.
Currently, in endemic areas, many countries have devel-
oped control measures for eradicating the disease in live-
stock animals. Vaccination is probably the most common
measure for controlling brucellosis; live attenuated vac-
cines were used. Unfortunately, because the vaccines could
cause animal abortion, infertility, weak offspring, and other
shortcomings their application was blocked [15]. In order
to overcome these disadvantages, researchers are trying to
develop new vaccines, and recombination vaccines were
produced [16]. Prediction of antigenic epitopes on protein
surfaces is important for vaccine design. Most existing
epitope prediction methods focus on protein sequences to
predict continuous epitopes linear in sequence. These pre-
diction methods are based upon the amino acid properties,
including immunoinformatic analysis and prediction of
B-cell epitopes, such as hydrophilicity [17], surface ac-
cessibility [18], secondary structure [19], flexibility [20],
ABCPred [21], COBEPro [22], and BepiPred [23]. With
the development of these bioinformatics methods, they
provide more cost-effective approaches for seeking Bru-
cella vaccines and brucellosis diagnostic antigens.
For diagnose specificity, monoclonal antibodies are the
best option, but a monoclonal antibody can recognize only
one unique epitope. The preparation of monoclonal anti-
bodies is time-consuming and laborious, and whether
monoclonal antibodies can be prepared in large batches
depends on the luck component. In the present work, we
used bioinformatic methods for B-cell epitope prediction
to predict B-cell epitopes of OMP16, OMP2b, OMP31,
and BP26; based on these predicted B-cell epitopes, we
designed a novel recombinant protein for serological
diagnostic of brucellosis. We expressed and purified
this recombinant protein and finally evaluated it for
its diagnostic utility with ELISA and Western blotting.
Our design can avoid the shortcomings of monoclonal
antibodies.
Methods
Computer modeling prediction of epitopes
Amino acid sequences of OMP16, OMP2b, OMP31,
and BP26 were obtained from the National Center for
Biotechnology Information (NCBI) Database at http://
www.ncbi.nlm.nih.gov. To ensure the accuracy of pre-
diction, three different epitope prediction software
programs based on the protein sequences were used to pre-
dict the most immunogenic linear B-cell epitopes:
Bepipred (http://www.cbs.dtu.dk/services/Bepipred/),
ABCpred (http://www.imtech.res.in/raghava/abcpred/), and
COBEpro (http://scratch.proteomics.ics.uci.edu/). To find
the presence or absence of predicted epitopes across spe-
cies, the BLASTP was performed.
Construction, expression, and purification of recombinant
proteins
First, the predicted B-cell epitopes were selected to con-
struct the recombinant outer membrane protein(rOmp).
Then adjacent epitopes were joined together by the linker
“GGGS.” The recombinant protein gene was synthesized
by Sangon Biotech (Shanghai, China), which had a six-
His-tag-encoding sequence at the 3´ end, by using codon
optimized to permit expression in Escherichia coli. The
synthetic gene was inserted in the bacterial expression
vector pET-28b (+) to generate the plasmid pET28b (+);
then the recombinant plasmid was transformed into E. coli
BL21 (DE3) cells to induce recombinant protein expression
with 0.2 mM isopropyl-β-D-thiogalactoside (IPTG).
The transformed E. coli BL21 cells were grown in a
shaker at 220 rpm and 37 °C, inoculated into 4 L of Luria-
Bertani (LB, containing 30 μg/ml kanamycin) at a dilution
of 1:100. When the optical density at 600 nm (OD600) of
the culture reached approximately 0.6, the culture was in-
duced by 0.2 mM IPTG. Induction was grown overnight,
and cells were collected by centrifugation. Aliquots of the
induced and noninduced cell cultures were analyzed by
SDS-PAGE prior to purification.
The collected cells were dissolved with a lysis buffer
(7 M guanidine hydrochloride, 50 mM Tris, 300 mM
NaCl, 0.1 % Triton X-100, DNase I, RNase, lysozyme,
pH= 8.0) and then homogenized by sonication on ice
(power 400 W, 20 min, ultrasonic 3 S, pause 5 S for a loop).
The lysate was clarified by centrifugation at 10,000 × g for
20 min at 4 °C; then the supernatant was collected for puri-
fication. The supernatant was gently shaken with 5 ml of
Ni-nitrilotriacetic acid (NTA). The column was pre-
equilibrated with a binding buffer (7 M Gua-Hcl, 50 mM
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Tris, 300 mM NaCl, pH = 8.0). After the flow-through was
collected, the column was washed extensively with wash
buffer (8 M urea, 50 mM Tris, 300 mM NaCl, 10/20/
50 mM imidazole, pH = 8.0) and elution buffer eluent (8 M
urea, 50 mM Tris, 300 mM NaCl, 500 mM imidazole, pH
= 8.0); the eluent was collected.
The purified rOmp protein was run on 12 % SDS-
PAGE gel and transferred to a polyvinylidene fluoride
(PVDF) membrane in a trans-blot system. After the
transfer, the membrane was blocked with 5 % skim milk
at 4 °C overnight, and then washed three times with
phosphate-buffered saline containing 0.05 % Tween 20
(PBST) and incubated with a rabbit anti-His-tag poly-
clonal antibody (at 1:1000 dilution) for 1 h at 37 °C. The
membrane was washed three times again, and incubated
with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit immunoglobulin (Ig)G antibodies at 1:10,000 dilu-
tions for 1 h at 37 °C. After washing again, the protein
bands were incubated in diaminobenzidine (DAB) sub-
strate solution for 15 min at 37 °C.
Concentrations of purified proteins were measured by
non-interference protein assay kit SK3071 (Sangon Bio-
tech,Shanghai, China), according to the instructions sup-
plied by the kit manufacturer.
Samples
248 serum samples from three different clinical groups
were provided by Plague and Brucellosis Prevention and
Control Base, Chinese CDC, Baicheng, Jilin, China:
(1) 146 serum brucellosis samples of culture-positive,
which were serologically positive by plate agglutin-
ation test (PAT) and standard tube agglutination test
(SAT) as standard methods for diagnosis of
brucellosis.
(2) 82 serum samples of non-brucellosis infected
other bacteria, including E. coli (5 serum samples),
Staphylococcus (10 serum samples), Proteus mir-
abilis (2 serum samples), Enterobacter cloacae (2
serum samples), Streptococcus salivarius (2 serum
samples), Streptococcus viridans (2 serum samples),
and Klebsiella pneumoniae (6 serum samples),
Salmonella enteritidis (1 serum samples), and fever
of unknown origin (62 serum samples).
(3) 20 serum samples of healthy individuals were
collected. The samples of non-brucellosis patients
and healthy donors were verified as non-brucellosis
by PAT and SAT.
Venous blood (5 ml) was collected from the patients
and healthy individuals; supernatants were harvested after
centrifugation at 1,200 g for 10 min and stored at −70 °C
until assayed. A titer of 1:100 and higher was considered
as a suspected positive result for brucellosis by PAT or
SAT, and blood culture was subsequently used for
verification.
IELISA and Western blot analysis
Ninety-six-well microtiter plates (Corning, USA) were
coated with 1 μg per well of the recombinant protein in
coating buffer (0.01 M PBS, pH 7.4) and incubated over-
night at 4 °C. After three washes with PBST, the plates
were blocked with 1 % bovine serum albumin (BSA, Sigma,
USA) for 2 h at 37 °C and then incubated with serum
1:400 in PBST containing 1 % BSA for 1 h at 37 °C. After a
washing step, a 1:10,000 diluted HRP-goat anti-human IgG
secondary antibody (Invitrogen, USA) was added and incu-
bated at 37 °C for 1 h. The plates were washed, and then
100 μl of the TMB substrate solution was added to each
well. Reactions were left to react for 15 minutes at room
temperature in a dark place. Finally, 50 μl of the stop solu-
tion (2 M H2SO4) was added to each well. ODs were mea-
sured at 450 nm using an ELISA plate reader (BioTek,
USA). Positive, negative, and blank (PBS) samples were
tested in triplicate, and the experiment was repeated three
times. All the samples were processed simultaneously.
Meanwhile, we used the antigen of SAT (the whole
bacteria antigen were supplied by Plague and Brucellosis
Prevention and Control Base) to evaluate the effective-
ness of our fusion protein as a diagnostic antigen for
brucellosis by IELISA.
Western blotting was performed partially as described
above. After recombinant proteins were transferred onto
the PVDF membrane, the membranes were blocked in
TBST containing 5 % skim milk overnight at 4 °C. Then
the membranes were incubated with human serum at
1:100 dilution for 2 h at room temperature. After a wash-
ing step with TBST, the membranes were incubated with a
1:10,000 HRP-conjugated goat anti-human IgG secondary
antibody for 1 h at room temperature (RT). After three
washes in TBST, protein detection was visualized with
the BeyoECL Plus Kit (Beyotime, China), following the
manufacturer's instructions, and exposed to X-ray film.
Each band was analyzed using a Gel Image System
(Tanon, China).
Statistical analysis
Dotplot and receiver-operating characteristic (ROC)
were performed using the GraphPad Prism version 6.05
for Windows.
Results
Computer modeling prediction of epitopes
The Accession Numbers of OMP16, OMP2b, OMP31, and
BP26 were obtained from NCBIDatabase(Additional file 1:
Table S3). To improve the accuracy of B-cell epitope pre-
diction, three different epitope-prediction software pro-
grams (ABCPred, BepiPred, and COBEPro) were used to
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predict the most immunogenic linear B-cell epitopes of
the fusion protein. We choose the 15 overlapping epitopes
that were predicted by the three methods as B-cell epitope
candidates (see Table 1), and the results of BLASTP indi-
cated these epitopes are highly conserved in Brucella.
Recombinant protein identification
To avoid emerging new epitopes, we separated each pre-
dicted epitope by a linker (Fig. 1). By optimizing codons
for E. coli expression, a resultant 1338-bp gene was synthe-
sized by Sangon Biotech. Then we inserted the synthetic
gene in the bacterial expression vector pET-28b and trans-
formed it into E. coli BL21 (DE3) cells. Then, the induced
cells were sonicated and analyzed by SDS-PAGE. A spe-
cific band representing the recombinant product was ob-
tained (Fig. 2a). Ni–NTA affinity purification was used,
and the purified products were analyzed by SDS-PAGE
(Fig. 2b and c). Starting from 1 g of the induced cell pellet,
we obtained 1 ml of rOmp protein solution with a concen-
tration of 1.2 mg/ml, as measured with a non-interference
protein assay kit (SK3071, Sangon Biotech).
IELISA
To evaluate the assay, 248 serum samples including bru-
cellosis (146 samples), non-brucellosis patients (82 sam-
ples) and healthy individuals (20 samples) were tested by
indirect ELISA and Western blotting. A dotplot diagram
outlined the OD values of these samples (Fig. 3a). A
ROC analysis was performed to evaluate the optimize
sensitivity and specificity (Fig. 3b). Based on the ROC
analysis, AUC for this test was 0.9409 (95 % confidence
interval (CI), 0.9108 to 0.9709). In addition, a diagnostic
sensitivity of 88.89 % (95 % CI, 82.06 to 93.79) and a
specificity of 85.54 % (95 % CI, 76.11 to 92.30) was ob-
tained from a optimum cutoff value(0.3865). With this
cutoff value, 135 of 146 brucellosis cases were diagnosed
correctly as positive, and only nine negative cases were
diagnosed incorrectly as positive; all of the healthy indi-
viduals can be diagnosed correctly.
Furthermore, we used the antigen of SAT to diagnose
brucellosis in IELISA, which was in parallel with the fu-
sion protein, a dotplot diagram (Fig. 3c), and ROC curve
(Fig. 3d). Based on same analysis, the AUC for the test
was 0.8981 (95 % CI, 0.8455 to 0.9508), a diagnostic sen-
sitivity of 86.99 % (95 % CI, 80.43 to 91.98)and a specifi-
city of 82.05 % (95 % CI, 66.46 to 92.46) was obtained
from a optimum cutoff value(0.5730). However, with the
cutoff value, 127 of 146 brucellosis cases were diagnosed
correctly, and 20 negative cases were diagnosed incor-
rectly, including seven healthy individuals diagnosed as
positive. We also have a cross-table with absolute num-
bers of positive and negative samples with these cutoff
values (Table 2).
The results of ELISA indicate that it is possible with
this assay to clearly discriminate between brucellosis
and non-brucellosis cases. Compared with the whole
bacterial antigen, rOMP has a weaker cross-reaction
(Additional file 2: Fig. S1).To further investigate isotype-
specific reactivity, IgM, IgG, and Ig(M+G) ELISA tests
were performed. We found that the IgG and Ig(M+G)
had similar results, but only a few brucellosis samples were
weakly IgM isotype positive. Compared with the antigen of
SAT, 45 brucellosis samples were IgM isotype positive
(Additional file 3: Table S2).
Additionally, the western blotting result indicates that
the antibody could specificity binding to the recombin-
ant protein of predicted B-cell epitopes.
Discussion
B-cell epitopes are the sites of molecules that are recog-
nized by antibodies of the immune system. Bioinformatics
is used for many purposes, especially for vaccine design
and diagnostic tests. These prediction methods are based
upon the properties of 20 amino acids, including immu-
noinformatic analysis and prediction of B-cell epitopes,
such as hydrophilicity [17], surface accessibility [18],
β-turn [19], and flexibility [20]. However, using bio-
informatic tools to predict immunogenic B-cell epitopes
remains a vital and challenging task because their rate of
successful prediction is not very high. To avoid the draw-
backs, three different epitope prediction software pro-
grams (ABCPred, BepiPred, and COBEPro) were used
to predict the most immunogenic linear B-cell epitopes
in this study.
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306–316 FNLQAAHDDW GKTAVTAN
328–354 TVT PEVSYTKFGG EWKDTVAEDN AWGG
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In the early 1980s and 1990s, the major outer proteins of
Brucella spp. were identified and characterized as potential
immunogenic and protective antigens. In recent studies,
several OMPs had been demonstrated to be highly immu-
noreactive; these include BP26, OMP16, OMP31, OMP2b,
and OMP25. In our study, we chose four OMPs (BP26,
OMP16, OMP31, and OMP2b), which exist in almost all
Brucella spp. We did not use OMP25 because it is present
mainly in B. abortus. We used ABCPred, BepiPred, and
COBEPro to predict the most immunogenic linear B-cell
epitopes in the four selected OMPs. To avoid inaccuracies,
we selected 15 overlapping epitopes that were predicted by
all three methods.
It is reported that laboratory testing and diagnosis of
brucellosis is critical for patient management [24].
Currently, numerous available diagnostic methods are
difficult to perform in developing countries with poor
resources, especially in endemic regions. IELISA is the
best choice for diagnosing brucellosis, especially when
other tests are limited. It can reveal total and individ-
ual specific immunoglobulins (IgG, IgM, IgA) rapidly
(within 6 h) with high sensitivity and specificity [25].
In our present study, we designed a novel antigen to de-
tect antibodies against Brucella spp. using an indirect
ELISA assay. The assay was assessed by using a series of
serum samples obtained from brucellosis, non-brucellosis
and healthy individuals. The sample characteristics are de-
scribed in Additional file 4: Table S1. All the samples are
from Baicheng city, which has a high incidence of bru-
cellosis in China. In this region, almost all farmers
breed livestock, which accounts for significant morbid-
ity of brucellosis.
To validate the assay, an immunoblot and ROC analysis
were performed. The result of AUC was 0.9409, indicating
our assay has high accuracy for human brucellosis diag-
nose by contrast with global summary statistics of diag-
nostic accuracy of AUC. Our method could distinguish
highly accurate (0.9 < AUC < 1) [26]. Because brucellosis
patients often have gastrointestinal symptoms and fever,
we chose patients with other bacterial infections as a por-
tion of the controls, such as E. coli, Staphylococcus, Sal-
monella enteritidis, and fever of unknown origin. These
patients are likely to be misdiagnosed. The Western blot
results indicate that the newly established method based
Fig. 1 Amino acid sequence of the recombinant protein in FAST format: “GGGS” is the linker
Fig. 2 Preparation and identification of recombinant protein. a SDS-PAGE of OMP-induced expression with 0.2 mM IPTG for different times
(M, marker; Lane 1, uninduced cells; Lane 2, supernatant of IPTG-induced cells for 2 h; Lane 3, deposition of IPTG-induced cells for 2 h; Lane 4,
supernatant of IPTG-induced cells for 4 h; Lane 5, deposition of IPTG-induced cells for 4 h). b SDS-PAGE of OMP purification (M, marker; Lane 1,
purified recombinant protein.). c Western blotting analysis of the purified recombinant protein using the anti-His-tag rabbit anti-His-tag polyclonal
antibody (M, marker; Lane 1, purified recombinant protein)
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on this recombinant protein is feasible to differentiate hu-
man brucellosis and non-brucellosis infections.
However, ELISA methods that detect IgG are sensitive
but have low specificity. Measurement of IgM levels has
lower sensitivity than IgG but is more specific [27]. In this
case, this recombinant protein has low sensitivity to diag-
nose brucellosis in acute infection. The other, because of
the confirmation in brucellosis reports of China, and in-
discriminate therapeutic regimen, the diagnosis of brucel-
losis often do not distinguish Brucella species. We did not
obtain any information of diagnostic value for different
Brucella species infection. However, a previous study has
confirmed that B. melitensis is the most prominent species
causing human brucellosis in China, accounting for more
than 80 % of the cases [28].
Conclusion
Herein, we validated the newly established IELISA assay
with a high diagnostic accuracy of human brucellosis. In
our study, a predicted recombinant protein from four major
OMPs of Brucella was expressed for the first time and has
been validated to diagnose human brucellosis. However, to
fully evaluate the recombinant protein for diagnosis, fur-
ther research will be necessitated for diagnostics of brucel-
losis caused by different Brucella spp. strains.
In addition,this recombinant protein based assay can




Ethics approval and consent to participate
The serum samples used in this study were obtained for
laboratory analysis. Written informed consent for sample
Fig. 3 IELISA analysis of serum samples. The analysis was performed considering positive control serum samples with culture-confirmed/serologically
positive brucellosis (146 sera) and negative control sera from patients with other diseases and healthy individuals (102 sera). a Dotplot of the rOMP
IELISA assay. b ROC analysis of rOMP IELISA assay results. c Dotplot of the SAT antigen IELISA assay results. d ROC analysis of SAT antigen
IELISA assay results
Table 2 Positive predictive value and negative predictive value
of different cutoff values
Cutoff value Positive Negative PPV (%) NPV (%)
TP FN TN FP
≥0.3865a 135 11 93 9 93.75 89.42
≥0.5730b 127 19 82 20 80.89 81.19
TP, true positives; TN, true negatives; FP, false positives; FN, false negatives;
PPV, positive predictive value (TP/TP + FP) × 100; NPV, negative predictive
value (TN/TN + FN) × 100
acutoff value is calculated by rOMP ELISA
bcutoff value is calculated by antigen of SAT ELISA
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analysis was obtained from the patients. This study was
approved by the Institutional Research Ethics Commit-
tee of Medicine, the School of Public Health, Jilin Uni-
versity, permit number: JLU2014-0303.
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